Cantor Fitzgerald Maintains Overweight on Trevi Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.
Cantor Fitzgerald analyst Josh Schimmer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and raises the price target from $25 to $30.